Takara Bio is a leading Contract Development & Manufacturing Organization (CDMO) that supports customers worldwide in the development of their regenerative medicine products. Takara Bio offers high-quality and innovative tools, as well as comprehensive and seamless manufacturing and quality-testing services for cell and gene therapy products.My role:Develop the company’s sales and position in the clinical therapy sector across Europe, Middle-East and Africa.Our extensive Cell & Gene Therapy portfolio is based on 20-years of experience in the field of Regenerative Medicine:- Product solutions include: • For T-cell immunotherapy: RetroNectin reagent, Anti-CD3 monoclonal antibody, T-cell culture media and CultiLife culture bags • For Stem Cell-based therapy: non-exclusive clinical-grade Human ES cell line, Human ES/iPS culture media, MSC culture media • Extensive Viral portfolio (Retrovirus, Lentivirus, Adeno- and adeno-associated viruses)- Service solutions include: • Clinical-grade hES cell line derivation • Cell processing (T-cells, NK cells, Hematopoietic stem cells) • Cell banking services (MCB/WCB) from your hES or hiPS cells. • Viral vector production (Retrovirus, Lentivirus, Adeno- and adeno-associated viruses, Herpes simplex virus, Sendai virus) • Storage management (MCB/WCB, MVSS/WVSS) • Quality testing • Stability testing • Transportation testingApplications: cell therapy, gene therapy, regenerative medicine...

Takara Bio Europe is a member of the Takara Bio Group, a leading supplier of tools for life scientists worldwide. We serve customers in a wide range of scientific settings, from academic institutions to biotechs and pharmaceuticals in Europe, Middle East and Africa.Through our brand names TAKARA®, CLONTECH® and CELLARTIS™ we develop innovative technologies in the fields of Cell Biology, Molecular Biology, Proteomics and Stem Cell Research. Our best-in-class products are backed by expert technical assistance, because good science needs great support.My role:Develop the company’s sales and position on the pharma, biotech, CRO and academic markets, by selling Takara’s Stem Cell portfolio (CELLARTIS™ brand) as solutions to customers.Our extensive Stem Cell portfolio is based on 15-years of experience in Stem Cell Research:- Products include: • Human iPS/ES cells, iPS-derived cardiomyocytes, iPS-derived hepatocytes • Hepatocyte differentiation kit • Media for iPS cells (RUO, xeno-free, GMP versions), primary hepatocytes- Services include: • Sourcing and reprogramming of human somatic cells to iPS cells • Gene editing of iPS cells (knock-out/in) • Single-cell cloning of iPS cells • Directed differentiation (hepatocytes, beta-cells, cardiomyocytes...) • GMP ES/iPS cell bankingApplications: drug discovery, preclinical drug development, disease modelling, regenerative medicine...

PostdocInUSA.com is a content website dedicated to help future and current international postdocs in USA.We aim to create an online community for former postdocs, postdoctoral associations/offices and university representatives to share tips and information to prospective and current postdocs visiting the website.Create your free Account/Profile and interact with PostdocInUSA community!

Texcell is a worldwide contract research organization (CRO) providing in vitro and in vivo GLP/GMP services to large pharmaceutical and biotechnology companies: cell bank manufacturing (MCB, WCB), viral safety testing, viral clearance studies and immunology profiling / toxicology of biotherapeutic products. Texcell is operating its services in Europe, USA and Asia.Expertise: mAb, recombinant proteins, gene & cell therapy, viral vaccines...All tests are designed in accordance with the EU or US Pharmacopoeia and EMEA or FDA guidelines.My roles:- Business Unit Cell Culture; Area: All Europe & Israel• Develop and manage sales of GMP cell bank manufacturing (MCB & WCB) with associated characterization and viral safety testing.- Business Unit Virology & Biosafety; Area: France, Italy and Switzerland• Develop and manage sales of in vitro and in vivo GLP/GMP safety testing services (e.g. detection of Adventitious agents, mycoplasma, TEM, F-PERT, retrovirus by infectivity, RCR/RCL/RCA detection...); biodistribution & biodissemination studies (Gene Therapy, CAR-T); virucidal norm and cleaning validation.- Liaison officer between Texcell-France (Headquarters) and Texcell-North America (Frederick, MD).- Representation of the company at international conferences.

Texcell operates a state-of-the-art GMP facility for the production of cell banks (Master Cell bank (MCB) & Working Cell Bank (WCB)) in compliance with GMP standards. You benefit from our long-term experience in viral safety testing for the release of cell banks fully characterized and tested in-house.My roles:• Develop and manage all sales of Cell Culture business unit in Europe and Israel.• Responsible for sales of package services including GMP cell bank manufacturing (MCB & WCB) with complete characterization and viral safety testing.My mission is to provide you outstanding cell banking services!

Title: Dengue virus induces mitochondrial elongation through impairment of Drp1-triggered mitochondrial fission.• Observed elongation of mitochondria during Dengue virus infection using confocal and electron microscopy, as well as live-cell imaging.• Revealed DENV NS4b and NS3 proteins enrichment in the mitochondrial fraction.• Analyzed mitochondrial respiration (oxygen consumption rate) using Seahorse Analyzer to address mitochondrial function during Dengue virus infection.• Analyzed levels of mitochondrial proteins in sub-cellular fractions by western blot.• Demonstrated that induction of mitochondrial fission reduces viral replication.Other projects: collaboration with Dr. Fitzgerald laboratory (University of Massachusetts Medical School)• Study of lncRNAs profile in primary cells (dendritic cells) infected by different viruses.• Analyze of inflammasome response during Dengue virus infection.

Title: Pastrel, a restriction factor for picorna-like viruses in Drosophila melanogaster.• Identified polymorphisms in pastrel gene correlated with the susceptibility of laboratory control flies to Drosophila C virus infection (collaboration with Pr. Jiggins Laboratory, Cambridge university)• Characterized Pastrel protein as a viral restriction factor by loss- and gain-of-function experiments in vivo and ex vivo.• Constructed deletion mutants to identify the domain conferring antiviral activity.• Determined the step of virus infectious cycle impacted by Pastrel.• Designed a new method to study the topology of Pastrel protein.• Analyzed Pastrel localization in non-infected and infected cells.Other projects:• Analyzed the effect of a persistent viral infection on the susceptibility of flies to pathogens.• Revealed the role of RNA interference in the control of a DNA virus in Drosophila.

Title: Effect of mutations in NS3 and 2K proteins on the pathogenicity of West Nile virus NY99.• Used West Nile virus NY99 infectious clone with mutations introduced in NS3 and/or 2K proteins.• Analyzed the effect of mutations on the infection of murine (Neuro2a) and human (IMR5) neuronal cells in vitro and on the pathogenicity of the virus in vivo in BALB/C mice.

Title: Study of PD1 expression on Treg lymphocytes in HIV-1 positive patients.• Isolated PBMCs and analyzed PD1 expression from Treg population by flow cytometry.

Title: Advantage of PCR on stools for the diagnostic of Adenovirus in patients transplanted by hematopoietic stem cells allograft.• Extracted viral DNA and performed real time qPCR to determine Adenovirus load from stools collected during patients’ hospitalization.• Retrieved virological analysis results and treatment history from patient’s records to demonstrate the advantage of this detection method.